BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/29/2014 11:31:00 AM | Browse: 1131 | Download: 610
Publication Name World Journal of Gastroenterology
Manuscript ID 6314
Country/Territory Japan
Received
2013-10-13 22:36
Peer-Review Started
2013-10-15 11:53
To Make the First Decision
2014-01-09 18:09
Return for Revision
2014-01-16 22:43
Revised
Second Decision
2014-02-27 11:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-27 11:57
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-03-26 18:39
Publish the Manuscript Online
2014-04-17 13:27
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI
Manuscript Source Invited Manuscript
All Author List Yasunori Minami, Naoshi Nishida and Masatoshi Kudo
Funding Agency and Grant Number
Corresponding Author Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, Osaka 589-8511, Japan. m-kudo@med.kindai.ac.jp
Key Words Hepatocellular carcinoma; Micrometastasis; Microvascular invasion; Radiofrequency ablation; Safety margin
Core Tip Radiofrequency ablation (RFA) therapy is needed to ablate wider range of region than targeted tumor, including surrounding liver tissues that involve micrometastases and microvascular invasion. The local recurrence rate tends to be lower in hepatocellular carcinoma patients with an adequate ablation margin, and thus, it is essential to assess safety margin accurately to reduce local recurrence. From this point of view, we need to focus on the achievement of a sufficient ablation margin as well the lack of tumor vascular enhancement for the assessment of successful RFA. However, inflammatory hyperemia due to RFA which often appears as peripheral rim enhancement, and non-typical imaging features of tumor recurrence sometimes lead to the inappropriate diagnosis.
Publish Date 2014-04-17 13:27
Citation Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI. World J Gastroenterol 2014; 20(15): 4160-4166
URL http://www.wjgnet.com/1007-9327/full/v20/i15/4160.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i15.4160
Full Article (PDF) WJG-20-4160.pdf
Full Article (Word) WJG-20-4160.doc
Manuscript File 6314-Review.doc
Answering Reviewers 6314-Answering reviewers.pdf
Copyright License Agreement 6314-Copyright assignment.pdf
Peer-review Report 6314-Peer review(s).pdf
Scientific Editor Work List 6314-Scientific editor work list.doc